Our Ambition
We believe the International Neuromodulation Registry represents a transformative resource for manufacturers, clinicians, and researchers working to advance care in the neuromodulation field. By enabling structured, real-world data collection on device performance, long-term outcomes, and patient-reported impact across multiple indications and geographies, the registry will accelerate evidence generation that supports regulatory decisions, market access, and responsible innovation.
We are confident the INR will become a transformative evidence platform for the neuromodulation community – advancing clinical excellence, regulatory compliance, and patient outcomes.
International
Neuromodulation
Registry
Target Groups and Their Benefits
- International Clinical Centres and Practitioners: Benefit from access to outcome benchmarks, peer comparisons, and decision-support analytics derived from aggregated international data.
- Patients and Patient Organisations: Gain from more transparent, evidence-based care, and future inclusion in governance and Patient Reported Outcome Measures (PROMs) design.
- Health Authorities and Policymakers: Use outputs to inform policy decisions, service planning, and registry-linked reimbursement models.
- Researchers and Academics: Access harmonised datasets across geographies to conduct cross-national epidemiological studies.
- Industry Stakeholders: Opportunity to engage via formal agreements to support post-market surveillance, health technology assessments, and real-world evidence generation support.